Drug Type Small molecule drug |
Synonyms Pitavastatin Calcium Hydrate/Ezetimibe, 依折麦布/匹伐他汀钙 + [3] |
Target |
Mechanism CETP inhibitors(Cholesteryl ester transfer protein inhibitors), HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date KR (28 Jul 2021), |
Regulation- |
Molecular FormulaC24H21F2NO3 |
InChIKeyOLNTVTPDXPETLC-XPWALMASSA-N |
CAS Registry163222-33-1 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypercholesterolemia | JP | 26 Sep 2022 | |
Hyperlipoproteinemia Type II | JP | 26 Sep 2022 | |
Primary hypercholesterolemia | KR | 28 Jul 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Homozygous familial hypercholesterolemia | Phase 1 | CN | 20 Sep 2022 | |
Primary hypercholesterolemia | Phase 1 | CN | 20 Sep 2022 | |
Hypercholesterolemia | IND Approval | CN | 20 Apr 2022 |